title: Late Major Hemoptysis After Lung Volume Reduction With Coils Induced by Dual Antiaggregation Therapy.
abstract: Lung-volume reduction using coils is an effective and safe treatment for selected patients presenting severe emphysema and hyperinflation. Most complications occur during the first 30 days after the procedure. Although frequent, hemoptysis is usually transient and minor. Antiaggregation therapy is common in patients with emphysema who, very often, have additional tobacco-associated comorbidities. Aspirin is considered safe for most major interventions; however, clopidogrel is mainly contraindicated and considered an exclusion criterion. We present a case of life-threatening hemoptysis caused by dual antiaggregation therapy "accidentally" introduced 3 months after the procedure. So far no recommendations exist on the optimal therapeutic strategy after lung-volume reduction with coils.
authors.affiliation: Respiratory Medicine Department, Regional Hospital of Lugano, Lugano, Switzerland.
authors.forename: Antonio
authors.initials: A
authors.lastname: Valenti
authors.affiliation: Medicine Department, Regional Hospital of Lugano, Lugano, Switzerland.
authors.forename: Alessio
authors.initials: A
authors.lastname: Casutt
authors.affiliation: Respiratory Medicine Department, University Hospital of Lausanne, Lausanne, Switzerland.
authors.forename: Angela
authors.initials: A
authors.lastname: Koutsokera
authors.affiliation: Haematology Department, University Hospital of Lausanne, Lausanne, Switzerland.
authors.forename: Jasmine
authors.initials: J
authors.lastname: Noetzli
authors.affiliation: Thoracic Surgery Department, University Hospital of Lausanne, Lausanne, Switzerland.
authors.forename: Jean Yannis
authors.initials: JY
authors.lastname: Perentes
authors.affiliation: Thoracic Surgery Department, University Hospital of Lausanne, Lausanne, Switzerland.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Krueger
authors.affiliation: Respiratory Medicine Department, Regional Hospital of Lugano, Lugano, Switzerland; Medicine Department, Regional Hospital of Lugano, Lugano, Switzerland.
authors.forename: Marco
authors.initials: M
authors.lastname: Pons
authors.affiliation: Respiratory Medicine Department, University Hospital of Lausanne, Lausanne, Switzerland.
authors.forename: Laurent P
authors.initials: LP
authors.lastname: Nicod
authors.affiliation: Respiratory Medicine Department, University Hospital of Lausanne, Lausanne, Switzerland. Electronic address: alban.lovis@chuv.ch.
authors.forename: Alban
authors.initials: A
authors.lastname: Lovis
mesh_terms: D001241:Aspirin / Q000009:adverse effects*; D000077144:Clopidogrel; D006469:Hemoptysis / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011013:Pneumonectomy / Q000295:instrumentation*; D011183:Postoperative Complications / Q000139:chemically induced*; D011656:Pulmonary Emphysema / Q000601:surgery; D012720:Severity of Illness Index; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D013997:Time Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin